PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study

(2020) Wassim Abida et al.   CLINICAL CANCER RESEARCH

Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors

(2020) Neelima Vidula et al.   CLINICAL CANCER RESEARCH

TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).

(2020) Johann S. De Bono et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted therapy based on germline analysis of tumor-normal sequencing (MSK-IMPACT) in a pan-cancer population.

(2020) Zsofia Kinga Stadler et al.   JOURNAL OF CLINICAL ONCOLOGY

An emerging landscape for canonical and actionable molecular alterations in primary and metastatic prostate cancer

(2020) Nancy A. Dawson et al.   MOLECULAR CANCER THERAPEUTICS

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

(2020) Nicholas R. Jette et al.   Cancers

DNA Repair and Prostate Cancer: A Field Ripe for Harvest

(2020) Alan H. Bryce et al.   EUROPEAN UROLOGY

Long‐Term Disease Control Using Taxane/ Platinum‐Based Chemotherapy in CDK12‐Mutated Advanced Prostate Cancer

(2020) Pedro Barata et al.   ONCOLOGIST

MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer

(2020) Arcadi Cipponi et al.   SCIENCE

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

(2019) Matthew Raymond Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

(2019) Patrick G. Pilié et al.   CLINICAL CANCER RESEARCH

Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand

(2019) Lin Mei et al.   Journal of Hematology & Oncology

Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer

(2019) Narges Ansari et al.   Labmedicine

Genomic correlates of clinical outcome in advanced prostate cancer

(2019) Wassim Abida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes

(2019) Anil Paul Chirackal Manavalan et al.   EMBO REPORTS

DNA Damage and Associated DNA Repair Defects in Disease and Premature Aging

(2019) Vinod Tiwari et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells

(2019) Nicholas R. Jette et al.   BRITISH JOURNAL OF CANCER

846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

(2019) W Abida et al.   ANNALS OF ONCOLOGY

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

(2019) Lisanne F. van Dessel et al.   Nature Communications

Genomics of lethal prostate cancer at diagnosis and castration resistance

(2019) Joaquin Mateo et al.   JOURNAL OF CLINICAL INVESTIGATION

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

(2019) Joaquin Mateo et al.   LANCET ONCOLOGY

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

(2018) C Cruz et al.   ANNALS OF ONCOLOGY

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

(2018) Yi-Mi Wu et al.   CELL

Update on PARP Inhibitors in Breast Cancer

(2018) Alexandra S. Zimmer et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

(2018) Philipp Nuhn et al.   EUROPEAN UROLOGY

The long tail of oncogenic drivers in prostate cancer

(2018) Joshua Armenia et al.   NATURE GENETICS

RPA and RAD51: fork reversal, fork protection, and genome stability

(2018) Kamakoti P. Bhat et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Super-resolution imaging identifies PARP1 and the Ku complex acting as DNA double-strand break sensors

(2018) Guang Yang et al.   NUCLEIC ACIDS RESEARCH

RPA and RAD51: fork reversal, fork protection, and genome stability

(2018) Kamakoti P. Bhat et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Mechanisms of PARP inhibitor sensitivity and resistance

(2018) Alan D. D’Andrea   DNA REPAIR

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions

(2018) Michal Zimmermann et al.   NATURE

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing

(2018) Sadakatsu Ikeda et al.   CANCER BIOLOGY & THERAPY

Development of PARP and Immune-Checkpoint Inhibitor Combinations

(2018) Ross A Stewart et al.   CANCER RESEARCH

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer

(2018) Katherine C. Kurnit et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

(2018) Gyorgy Petrovics et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

(2018) Fatima Karzai et al.   Journal for ImmunoTherapy of Cancer

Mechanisms of DNA damage, repair, and mutagenesis

(2017) Nimrat Chatterjee et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

(2017) Stephanie A. Yazinski et al.   GENES & DEVELOPMENT

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

(2017) Mohammad Asim et al.   Nature Communications

ATM Mutations in Cancer: Therapeutic Implications

(2016) M. Choi et al.   MOLECULAR CANCER THERAPEUTICS

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

(2016) Colin C. Pritchard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

(2016) Y. Pommier et al.   Science Translational Medicine

SnapShot: Fanconi Anemia and Associated Proteins

(2015) Anderson T. Wang et al.   CELL

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

The Molecular Taxonomy of Primary Prostate Cancer

(2015) Adam Abeshouse et al.   CELL

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

(2015) G. Kim et al.   CLINICAL CANCER RESEARCH

Error-free and mutagenic processing of topoisomerase 1-provoked damage at genomic ribonucleotides

(2015) J. L. Sparks et al.   EMBO JOURNAL

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer

(2015) Malcolm D. Mason et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data

(2015) Thomas W. Flaig et al.   Cancer Medicine

Ribonuclease H2 in health and disease

(2014) Martin A.M. Reijns et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer

(2014) Colin C. Pritchard et al.   Nature Communications

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

(2013) I. Bajrami et al.   CANCER RESEARCH

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Repair of Double-Strand Breaks by End Joining

(2013) K. K. Chiruvella et al.   Cold Spring Harbor Perspectives in Biology

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers

(2013) W. R. Polkinghorn et al.   Cancer Discovery

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Molecular pathogenesis and clinical management of Fanconi anemia

(2012) Younghoon Kee et al.   JOURNAL OF CLINICAL INVESTIGATION

Quantitative Live Cell Imaging Reveals a Gradual Shift between DNA Repair Mechanisms and a Maximal Use of HR in Mid S Phase

(2012) Ketki Karanam et al.   MOLECULAR CELL

Dual Roles of PARP-1 Promote Cancer Growth and Progression

(2012) M. J. Schiewer et al.   Cancer Discovery

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes

(2011) D. Blazek et al.   GENES & DEVELOPMENT

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

(2011) Neil Johnson et al.   NATURE MEDICINE

CHEK2 gene alterations in the forkhead-associated domain, 1100delC and del5395 do not modify the risk of sporadic pancreatic cancer

(2010) Beatrice Mohelnikova-Duchonova et al.   Cancer Epidemiology

The DNA Damage Response: Making It Safe to Play with Knives

(2010) Alberto Ciccia et al.   MOLECULAR CELL

Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination

(2010) Rémi Buisson et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2

(2010) Eloïse Dray et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

How the Fanconi Anemia Pathway Guards the Genome

(2009) George-Lucian Moldovan et al.   Annual Review of Genetics

Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

(2009) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2

(2009) Andrea Beucher et al.   EMBO JOURNAL

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Homologous recombination in DNA repair and DNA damage tolerance

(2008) Xuan Li et al.   CELL RESEARCH

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

(2008) R. W. Tothill et al.   CLINICAL CANCER RESEARCH

MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks

(2008) L. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA